The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.
Clinical trial NCT07338981 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07338981
- Sponsor
- Guliz Ozgun
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-01
- Primary completion
- 2030-12-01
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.